Skip to main content
Log in

Identification of a novel non-functional CYP2D6 allele, CYP2D6*69, in a Caucasian poor metabolizer individual

  • Short Communication
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

References

  1. Zanger UM, Raimundo S, Eichelbaum M (2004) Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedeberg’s Arch Pharmacol 369:23–37

    Article  CAS  Google Scholar 

  2. Tomalik-Scharte D, Jetter A, Kinzig-Schippers M et al (2005) Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. Drug Metab Dispos 33:1859–1866

    PubMed  CAS  Google Scholar 

  3. Wyen C, Fuhr U, Frank D et al (2008) Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin Pharmacol Ther 84:75–82

    Article  PubMed  CAS  Google Scholar 

  4. Gaedigk A, Simon SD, Pearce RE et al (2008) The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 83:234–242

    Article  PubMed  CAS  Google Scholar 

  5. Fukuda T, Nishida Y, Imaoka S et al (2000) The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6. Arch Biochem Biophys 380:303–308

    Article  PubMed  CAS  Google Scholar 

  6. Raimundo S, Toscano C, Klein K et al (2004) A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clinical Pharmacol Ther (CPT) 76:128–138

    Article  CAS  Google Scholar 

  7. Shen H, He MM, Liu H et al (2007) Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab Dispos 35:1292–1300

    Article  PubMed  CAS  Google Scholar 

  8. Soyama A, Saito Y, Kubo T et al (2006) Sequence-based analysis of the CYP2D6*36-CYP2D6*10 tandem-type arrangement, a major CYP2D6*10 haplotype in the Japanese population. Drug Metab Pharmacokinet 21:208–216

    Article  PubMed  CAS  Google Scholar 

  9. Toscano C, Klein K, Blievernicht J et al (2006) Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events. Pharmacogenet Genomics 16:755–766

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We thank Mrs Liliane Ndjountché for technical assistance.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Andrea Gaedigk.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gaedigk, A., Frank, D. & Fuhr, U. Identification of a novel non-functional CYP2D6 allele, CYP2D6*69, in a Caucasian poor metabolizer individual. Eur J Clin Pharmacol 65, 97–100 (2009). https://doi.org/10.1007/s00228-008-0559-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-008-0559-6

Keywords

Navigation